ASH 2021 Conference Coverage on VuMedi

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2021 Conference Coverage on VuMedi

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
COVID-19 and Blood Cancers

Playback speed

10 seconds

ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Patients With NDMM Treated With D-Rd vs. Rd: Update of the Phase 3 MAIA Trial

By ASH 2021 Conference Coverage on VuMedi FEATURING Aurore Perrot

83 views

February 26, 2022

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Myeloma

ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Pat…

ASH 2021 Conference Coverage on VuMedi

A. Perrot

83 views

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

ASH 2021 Conference Coverage on VuMedi

A. Jakubowiak

187 views

2022 Updates on CAR T-Cell Therapy for Myeloma

ASH 2021 Conference Coverage on VuMedi

L. Anderson

43 views

ASH 2021 Update on the Impact of EPd on HRQoL for Patients With R/R …

ASH 2021 Conference Coverage on VuMedi

K. Weisel

295 views

ASH 2021 on the Efficacy and Safety of Cilta-cel in Len-Refractory P…

ASH 2021 Conference Coverage on VuMedi

Y. C. Cohen

61 views

ASH 2021 Updated Results From the Phase I CRB-402 Study of the BCMA-…

ASH 2021 Conference Coverage on VuMedi

N. S. Raje

13 views

ASH 2021 Review of MRD in MM: Why, When, Where, and How?

ASH 2021 Conference Coverage on VuMedi

N. S. Raje

179 views

ASH 2021: Addressing Current Questions and Controversies in the Mana…

ASH 2021 Conference Coverage on VuMedi

M. Gertz

388 views

ASH 2021 Update on Cilta-Cel for Triple-Class Exposed MM: Adjusted C…

ASH 2021 Conference Coverage on VuMedi

M. Mateos

121 views

ASH 2021 on the Safety, Tolerability, PK/PD, and Preliminary Efficac…

ASH 2021 Conference Coverage on VuMedi

N. Shah

64 views

ASH 2021: Risk of Infections With BCMA-Directed Immunotherapy in Mul…

ASH 2021 Conference Coverage on VuMedi

M. Mohan

85 views

ASH 2021 Updates on Outcomes in HR-MM Treated With Daratumumab

ASH 2021 Conference Coverage on VuMedi

F. van Rhee

116 views

ASH 2021 Highlights on Treatment Options for AL Amyloidosis Patients…

ASH 2021 Conference Coverage on VuMedi

E. Kastritis

103 views

ASH 2021: Genomic and Immune Signatures Predict Sustained MRD Negati…

ASH 2021 Conference Coverage on VuMedi

E. Boyle

166 views

ASH 2021 Update on the Efficacy and Safety of Ruxolitinib and Steroi…

ASH 2021 Conference Coverage on VuMedi

J. Berenson

123 views

ASH 2021 Lecture on Clinical Outcomes of R/R MM Patients Following T…

ASH 2021 Conference Coverage on VuMedi

T. Mouhieddine

73 views